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Gentamicin-based  prophylaxis  in tunnelled  indwelling
central venous  catheter  limbs  for haemodialysis  do  not
result in  bacterial  resistances  after a 9 year  follow  up
period
La  proﬁlaxis  con  gentamicina  de  las  ramas  del  catéter  venoso  central
permanente  tunelizado  en  hemodiálisis  no  causa  resistencia
bacteriana  durante  9  an˜os  de  evoluciónJuan Fernandez-Gallego ∗, Luis Cermen˜o,  Edison Rudas
 Mála
years); 60 patients (48%) were women, 39 patients (31%) hadServicio de Nefrología, Hospital Regional Universitario Carlos Haya,
To the Editor,
Between July 2003 and June 2012, 365 patients received dialysis
in our unit. 179 patients had an AV ﬁstula. 186 had a central
venous catheter (CVC); of whom 60 were excluded because
they had been treated within the previous month with gen-
tamicin (G) for various reasons. Of the 126 patients studied,
118 had a CVC in the internal jugular vein and 8 had it in the
femoral vein. Any procedure involving the CVC employed a
strict protocol of complete asepsis.1 Prophylaxis: intraluminal
post-HD locking with 5 mg  Gentamicin (G) + sodium heparin
at 1% or 5% per limb. For 6 months, the trough serum level
of G was measured (normal value: 0.2–2 g/mL), subsequently
changing to annual controls. If the level was >0.3–0.5 g/mL,
we reduced the lock to 3 mg/limb of G 0.5–2 mg/limb. The
diagnosis of CVCB was based on the criteria of Beathard and
Urbanes1 and the NKF guidelines on vascular access published
in 20062: clinical improvement in a patient with fever treated
with antibiotics with or without removal of CVC, with positive
blood cultures (BC+) normally from blood taken from the HD
line and/or infrequently from the CVC limb, having excluded
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other foci of infection. All patients with CVCB had BC+, except
one with BC−.
Treatment of CVCB. Gram positive organisms, vancomycin
1 g at the 1st HD and 500 mg  at subsequent HDs for 3–4
weeks, or another antibiotics if appropriate; Gram negative,
as indicated in the susceptibility testing, for 3–4 weeks. Key
outcomes studied: ototoxicity: clinical hypoacusis and/or ver-
tigo. Bacterial resistance to G: organisms normally sensitive
to G: Gram+: coagulase negative Staphylococcus aureus sen-
sitive to methicillin. Gram−:  Escherichia coli, Proteus,  Serratia,
Klebsiella, Enterobacter, Pseudomona aeruginosa,  etc. The mini-
mum inhibitory concentration (MIC) of G for these bacteria is
≤4 g/mL. Resistance was detected from the results of BCs and
susceptibility testing, which expressed sensitivity (S) or resis-
tance (R) to G and the MIC value for each organism. We  present
the other variables studied in the results section.
Results. The mean patient age was 68 ± 29 years (21–85E. La proﬁlaxis con gentamicina de las ramas del catéter venoso
cteriana durante 9 an˜os de evolución. Nefrologia. 2015;35:418–419.
. Fernandez-Gallego).
diabetes. The mean time each patient remained in the study
was 24 months. Thirty-eight patients were treated with pro-
phylaxis for >30 months (30% of all study patients), mean time
vier España, S.L.U. This is an open access article under the CC
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er patient was 50 months (31–108). On susceptibility testing,
o resistance was detected in G-sensitive bacteria: the MCI
as <4 g/mL, except in two cases of CVCB due to methicillin-
esistant Staphylococcus aureus,  and one case with BC(−).
No patients had a diagnosis of ototoxicity. The mean trough
evel of G per patient was 0.17 g/mL (0.05–0.31). The mean
 lock per limb per patient was 3 mg (2–5), equivalent to
.1–1.7 mg/mL/limb depending on the volume of the limb
ccording to the type of catheter.
Patients diagnosed with CVCB: 11(8.7%). Patients admitted
o hospital for CVCB: 4 (3.2%). Number of CVCB/CVC/1000 days:
.17. CVC removed due to CVCB: 3 patients (2.4%). Mortal-
ty due to CVCB: 1 (0.8%). Number of CVCB: 15, Staphylococcus
ureus: 8; Staphylococcus epidermidis:  4; Escherichia coli: 1; Strepto-
occus bovis: 1, and BC(−): 1. CVC was removed due to recurrent
VCB in one patient, for failure to improve clinically of in one
atient, and due to BC(−) in one patient with clinical remis-
ion. There were no other CVCB complications (endocarditis,
pondylodiscitis), except in one patient who died due to sepsis.
Discussion. The scientiﬁc literature demonstrates that in
D patients, prophylaxis with post-HD antibiotic locking of
VC limbs, including G, reduces morbidity and mortality
rom bacterial infection associated with CVCB (number of
VCB/CVC/1000 days, mortality and hospital admission due
o CVCB) compared with patients with heparin lock alone.3
acterial resistance to G has been reported.4 However, our
xperience since July 2003 in patients with CVC attending
o the unit and treated with G locking in doses lower than
hose given in other units (a detail we consider fundamental
ue to iatrogenic effects), no bacterial resistance or ototoxic-
ty was demonstrated after 9 years of follow-up.3 Having seen
ur results, we  must refer to the publication by Beathar and
rbanes1 in which they rate the quality of care of a HD unit
ccording to the number of CVCB/CVC/1000 days it obtains
hen complete asepsis is employed, an excellent result being
 value ≤1. In our case, the practice of complete asep-
is + prophylaxis meant that the number of CVCB/CVC/1000
ays was 0.17. Although we  are unable to compare another
he relationship  between  seru
unction in  pediatric  renal  tran
elación  entre  niveles  de  NGAL  en
n  pacientes  pediátricos  trasplanta
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study, in 9 years, to obtain a mortality, removal of CVC, and
hospital admission due to CVCB of 0.8%, 2.4%, and 3.2%,
respectively, is an appreciable standard, obtained thanks to
G prophylaxis + universal asepsis. This is further underlined
by the absence of endocarditis or spondylodiscitis, except for
one patient who died due to sepsis. Strict complete asepsis5
for all handling procedures of CVC is integral to prophylaxis
in reducing morbidity and mortality from bacterial infection
associated with CVCB.
Conclusions. This prospective observational study of 9
years’ duration in 126 HD patients with a CVC showed: (1) Pro-
phylaxis with intraluminal G locking in CVC limbs does not
cause antibiotic resistance in microorganisms sensitive to the
antibiotic. (2) There were no diagnoses of clinical ototoxicity,
and (3) Prophylaxis with administration of low-dose G (com-
pared with higher doses in other studies)3 can result in the
absence of resistance and ototoxicity.
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We  previously serially measured the serum and urine neu-
trophil gelatinase associated lipocalin (NGAL) during the ﬁrst
